[go: up one dir, main page]

RU2018133158A3 - - Google Patents

Download PDF

Info

Publication number
RU2018133158A3
RU2018133158A3 RU2018133158A RU2018133158A RU2018133158A3 RU 2018133158 A3 RU2018133158 A3 RU 2018133158A3 RU 2018133158 A RU2018133158 A RU 2018133158A RU 2018133158 A RU2018133158 A RU 2018133158A RU 2018133158 A3 RU2018133158 A3 RU 2018133158A3
Authority
RU
Russia
Application number
RU2018133158A
Other versions
RU2737324C2 (ru
RU2018133158A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018133158A publication Critical patent/RU2018133158A/ru
Publication of RU2018133158A3 publication Critical patent/RU2018133158A3/ru
Application granted granted Critical
Publication of RU2737324C2 publication Critical patent/RU2737324C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4748Quinolines; Isoquinolines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
RU2018133158A 2016-02-22 2017-02-20 Способы применения агонистов fxr RU2737324C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662298113P 2016-02-22 2016-02-22
US62/298,113 2016-02-22
PCT/IB2017/050962 WO2017145040A1 (en) 2016-02-22 2017-02-20 Methods for using fxr agonists

Publications (3)

Publication Number Publication Date
RU2018133158A RU2018133158A (ru) 2020-03-24
RU2018133158A3 true RU2018133158A3 (ru) 2020-06-08
RU2737324C2 RU2737324C2 (ru) 2020-11-27

Family

ID=58192341

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018133158A RU2737324C2 (ru) 2016-02-22 2017-02-20 Способы применения агонистов fxr

Country Status (17)

Country Link
US (2) US11110083B2 (ru)
EP (2) EP3842043A1 (ru)
JP (1) JP6941109B2 (ru)
KR (1) KR20180115700A (ru)
CN (1) CN108697703A (ru)
AU (1) AU2017223154B2 (ru)
CA (1) CA3014733A1 (ru)
DK (1) DK3419624T3 (ru)
ES (1) ES2862194T3 (ru)
HU (1) HUE053743T2 (ru)
IL (1) IL261036A (ru)
PL (1) PL3419624T3 (ru)
PT (1) PT3419624T (ru)
RU (1) RU2737324C2 (ru)
SI (1) SI3419624T1 (ru)
TW (1) TW201733583A (ru)
WO (1) WO2017145040A1 (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11229634B2 (en) 2016-02-22 2022-01-25 Novartis Ag Methods for treating gastrointestinal disorders using FXR agonists
RU2743075C2 (ru) * 2016-02-22 2021-02-15 Новартис Аг Способы применения агонистов fxr
JOP20190040A1 (ar) * 2016-09-14 2019-03-10 Novartis Ag توليفة من ناهضات fxr
AU2017339826A1 (en) * 2016-10-05 2019-04-04 Novartis Ag Combination compositions comprising FXR agonists for treating or preventing a fibrotic,cirrhotic disease or disorder
CN108017636A (zh) * 2016-11-04 2018-05-11 合帕吉恩治疗公司 作为fxr调节剂的含氮杂环化合物
AR114930A1 (es) 2017-09-12 2020-11-11 Novartis Ag Composición farmacéutica
WO2019053582A1 (en) * 2017-09-13 2019-03-21 Novartis Ag COMBINATIONS HAVING FXR AGONISTS
AU2018360575A1 (en) 2017-11-01 2020-06-18 Bristol-Myers Squibb Company Alkene spirocyclic compounds as farnesoid X receptor modulators
KR102732404B1 (ko) 2017-11-01 2024-11-19 브리스톨-마이어스 스큅 컴퍼니 파르네소이드 x 수용체 조정제로서의 알켄 화합물
JP7264905B2 (ja) 2017-11-01 2023-04-25 ブリストル-マイヤーズ スクイブ カンパニー ファルネソイドx受容体モジュレーターとしての多環化合物
KR102731924B1 (ko) 2017-11-01 2024-11-19 브리스톨-마이어스 스큅 컴퍼니 파르네소이드 x 수용체 조정제로서의 스피로시클릭 화합물
SG11202003827YA (en) 2017-11-01 2020-05-28 Bristol Myers Squibb Co Bridged bicyclic compounds as farnesoid x receptor modulators
CA3081656A1 (en) * 2017-11-30 2019-06-06 Novartis Ag Fxr agonists for the treatment of liver diseases
US11667629B2 (en) 2017-12-22 2023-06-06 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Isoxazole derivative, preparation method therefor, and use thereof
EP3852735A4 (en) * 2018-09-18 2022-06-08 Metacrine, Inc. FARNESOID-X RECEPTOR AGONISTS FOR THE TREATMENT OF DISEASES
EP3924329A2 (en) 2019-02-15 2021-12-22 Bristol-Myers Squibb Company Substituted amide compounds useful as farnesoid x receptor modulators
AR118050A1 (es) 2019-02-15 2021-09-15 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
US12319676B2 (en) 2019-02-15 2025-06-03 Bristol-Myers Squibb Company Substituted amide compounds useful as farnesoid X receptor modulators
JP7465883B2 (ja) 2019-02-15 2024-04-11 ブリストル-マイヤーズ スクイブ カンパニー ファルネソイドx受容体モジュレータとしての置換二環式化合物
US20220241376A1 (en) 2019-07-18 2022-08-04 Enyo Pharma Method for decreasing adverse-effects of interferon
KR20220035366A (ko) * 2019-07-18 2022-03-22 엔요 파마 Eyp001을 사용하는 개선된 치료
JP2022550312A (ja) * 2019-09-30 2022-12-01 ノバルティス アーゲー Fxrアゴニストの使用を含む処置
EP4090327B1 (en) 2020-01-15 2025-03-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fxr agonists for treating an infection by hepatitis d virus
JP2024502673A (ja) 2021-01-14 2024-01-22 ウエヌイグレックオ・ファーマ Hbv感染の処置のためのfxrアゴニストとifnの相乗効果
CN114903905B (zh) * 2021-02-09 2024-04-02 中国人民解放军陆军军医大学第二附属医院 甘氨脱氧胆酸在制备治疗肝内胆汁淤积药物中的应用及其药物组合物
CA3213217A1 (en) 2021-04-28 2022-11-03 Raphael Darteil Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003290700A1 (en) * 2002-11-22 2004-06-18 Smithkline Beecham Corporation Farnesoid x receptor agonists
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
RU2743075C2 (ru) 2016-02-22 2021-02-15 Новартис Аг Способы применения агонистов fxr
US11229634B2 (en) 2016-02-22 2022-01-25 Novartis Ag Methods for treating gastrointestinal disorders using FXR agonists

Also Published As

Publication number Publication date
WO2017145040A1 (en) 2017-08-31
EP3419624B1 (en) 2021-01-13
EP3842043A1 (en) 2021-06-30
US20210386729A1 (en) 2021-12-16
CA3014733A1 (en) 2017-08-31
AU2017223154A1 (en) 2018-08-30
IL261036A (en) 2018-10-31
JP2019511476A (ja) 2019-04-25
JP6941109B2 (ja) 2021-09-29
AU2017223154B2 (en) 2019-08-15
PL3419624T3 (pl) 2021-08-02
ES2862194T3 (es) 2021-10-07
CN108697703A (zh) 2018-10-23
US11110083B2 (en) 2021-09-07
HUE053743T2 (hu) 2021-07-28
DK3419624T3 (da) 2021-04-19
EP3419624A1 (en) 2019-01-02
KR20180115700A (ko) 2018-10-23
TW201733583A (zh) 2017-10-01
RU2737324C2 (ru) 2020-11-27
RU2018133158A (ru) 2020-03-24
HK1257649A1 (en) 2019-10-25
US20190083481A1 (en) 2019-03-21
SI3419624T1 (sl) 2021-05-31
PT3419624T (pt) 2021-04-07

Similar Documents

Publication Publication Date Title
BR112019001667A2 (ru)
RU2018133158A3 (ru)
BR212018070320U2 (ru)
BR112018071172A2 (ru)
BE2016C036I2 (ru)
BE2016C010I2 (ru)
CN303538877S (ru)
CN303538867S (ru)
CN303660815S (ru)
CN303536049S (ru)
CN303647708S (ru)
CN303608253S (ru)
CN303590646S (ru)
CN303535546S (ru)
CN303535544S (ru)
BY21942C1 (ru)
CN303588382S (ru)
CN303584364S (ru)
CN303563879S (ru)
CN303538743S (ru)
CN303563021S (ru)
CN303538954S (ru)
CN303538891S (ru)
CN303538883S (ru)
CN303537277S (ru)